Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

NCT05538572 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT05538572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05538572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 27, 2022
Completion date
June 26, 2024
Enrollment
22 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, endometrial cancer, glioblastoma, head and neck squamous cell carcinoma, malignant mesothelioma, non-small cell lung cancers, sarcoma